Oragenics issued new patent for novel antibiotic peptide

NewsGuard 100/100 Score

Oragenics has announced that the US Patent office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company's exclusively licensed novel antibiotic peptide, MU1140.

The patent claims include uses of the antimicrobial peptide for the treatment and prevention of bacterial infections.

Dr. Jeffrey Hillman, Oragenics' Chief Scientific Officer and the inventor of the patented MU1140 technology, stated, "This recently issued patent provides additional intellectual property protection for our lead antibiotic compound. MU1140 represents a major new class of antibiotics and one day could become a clinically useful tool against those bacteria that have grown resistant to existing antibiotics." Oragenics plans to complete by the end of this year the preclinical tests necessary to begin a human clinical trial with its promising molecule, MU1140.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
UQ researchers use new dosing technology to enhance ICU antibiotic treatment